Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | UBE2M | P61081 | 5/20 | 0.46 |
| ▸ | DCUN1D1 | Q96GG9 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23699905 | 0.91 | UBE2M (0.51) | LMNAUBE2MDCUN1D1ALDH1A1GAA | |
| SCHEMBL23699896 | 0.90 | LMNA (0.46) | LMNAUBE2MDCUN1D1ALDH1A1GAA | |
| SCHEMBL23699901 | 0.90 | LMNA (0.46) | LMNAUBE2MDCUN1D1ALDH1A1GAA | |
| SCHEMBL23699887 | 0.89 | LMNA (0.47) | LMNAUBE2MDCUN1D1ALDH1A1GAA | |
| SCHEMBL23200189 | 0.89 | LMNA (0.46) | LMNAUBE2MDCUN1D1ALDH1A1GAA | |
| SCHEMBL23200066 | 0.88 | POLB (0.55) | LMNAUBE2MDCUN1D1ALDH1A1GAA | |
| SCHEMBL23200130 | 0.88 | LMNA (0.48) | LMNAUBE2MDCUN1D1ALDH1A1GAA | |
| SCHEMBL23699972 | 0.88 | LMNA (0.47) | LMNAUBE2MDCUN1D1ALDH1A1GAA | |
| SCHEMBL23200040 | 0.88 | GAA (0.46) | LMNAUBE2MDCUN1D1ALDH1A1GAA | |
| SCHEMBL23699961 | 0.88 | UBE2M (0.46) | LMNAUBE2MDCUN1D1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | E-THERAPEUTICS PLC (GB) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | TPH1, KYNU, TPH2 | LMNA 4541/4885UBE2M 3929/4885DCUN1D1 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.